SCHEMBL9860818

SCHEMBL9860818

O=C(O)Nc1nc2cc([S+]([O-])c3ccccc3)ccc2[nH]1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 9/20 0.47
RAB9A P51151 9/20 0.47
PKM P14618 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
MAOB P27338 1/20 0.47
ADORA2A P29274 1/20 0.47
LMNA P02545 2/20 0.46
CYP3A4 P08684 1/20 0.46
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
ALDH1A1 P00352 2/20 0.44
MAPK1 P28482 1/20 0.44
HSD17B10 Q99714 1/20 0.44
KLF5 Q13887 2/20 0.43
SCD O00767 1/20 0.43
OPRK1 P41145 1/20 0.43
TP53 P04637 1/20 0.41
ALOX12 P18054 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11219230 0.90 ABL1 (0.47) NPC1RAB9APKMSMN1; SMN2MAOB
Oxfendazole SCHEMBL29409244 0.88 LMNA (0.55) NPC1RAB9ASMN1; SMN2ADORA2ALMNA
Oxfendazole SCHEMBL44121 0.88 LMNA (0.55) NPC1RAB9ASMN1; SMN2ADORA2ALMNA
Oxfendazole SCHEMBL27586080 0.87 LMNA (0.54) NPC1RAB9ASMN1; SMN2ADORA2ALMNA
SCHEMBL8411241 0.84 ALDH1A1 (0.48) NPC1RAB9APKMSMN1; SMN2MAOB
Oxfendazole SCHEMBL28641495 0.83 LMNA (0.50) NPC1RAB9ASMN1; SMN2ADORA2ALMNA
SCHEMBL11532983 0.82 ALDH1A1 (0.46) NPC1RAB9APKMSMN1; SMN2MAOB
SCHEMBL10902961 0.82 NPC1 (0.42) NPC1RAB9APKMSMN1; SMN2MAOB
SCHEMBL11259731 0.81 MAPT (0.36) NPC1RAB9APKMSMN1; SMN2MAOB
SCHEMBL11589337 0.81 SMN1; SMN2 (0.42) NPC1RAB9APKMSMN1; SMN2MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0060810-B1 ANTHELMINTICS CIBA-GEIGY AG (CH) 1984-10-17 EP claimed
US-4076827-A Method of treating helminthiasis by parenteral administration of sulfoxide derivatives of benzimidazoles E. R. SQUIBB & SONS, INC. (US) 1978-02-28 US claimed
US-11935803-B2 Resin composition, laminate, semiconductor wafer with resin composition layer, substrate for mounting semiconductor with resin composition layer and semiconductor device MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2024-03-19 US disclosed
CN-112004845-B Resin composition, laminate, semiconductor wafer with resin composition layer, substrate, and semiconductor device 三菱瓦斯化学株式会社 2022-05-31 CN disclosed
US-20220008542-A1 ANTI-PROTOZOAL COMPOUNDS AND USES THEREOF UNIV AUBURN (US) 2022-01-13 US disclosed
US-11160867-B2 Anti-protozoal compounds and uses thereof AUBURN UNIVERSITY (US) 2021-11-02 US disclosed
US-20210277221-A1 RESIN COMPOSITION, LAMINATE, SEMICONDUCTOR WAFER WITH RESIN COMPOSITION LAYER, SUBSTRATE FOR MOUNTING SEMICONDUCTOR WITH RESIN COMPOSITION LAYER AND SEMICONDUCTOR DEVICE MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2021-09-09 US disclosed
EP-3786200-A1 RESIN COMPOSITION, LAMINATE, RESIN COMPOSITION LAYER-ATTACHED SEMICONDUCTOR WAFER, SUBSTRATE FOR MOUNTING RESIN COMPOSITION LAYER-ATTACHED SEMICONDUCTOR, AND SEMICONDUCTOR DEVICE MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2021-03-03 EP disclosed
CN-112004845-A Resin composition, laminate, semiconductor wafer with resin composition layer, substrate for mounting semiconductor with resin composition layer, and semiconductor device 三菱瓦斯化学株式会社 2020-11-27 CN disclosed
CN-110693830-A Veterinary oxfendazole nano suspension and preparation method thereof 华中农业大学 2020-01-17 CN disclosed
US-20180326072-A1 ANTI-PROTOZOAL COMPOUNDS AND USES THEREOF AUBURN UNIVERSITY 2018-11-15 US disclosed
EP-0279343-B1 COMBINATIONS OF ANTHELMINTICALLY ACTIVE AGENTS BAYER AG (DE) 1991-06-05 EP disclosed
EP-0146556-A4 POTENTIATION OF ANTHELMINTICS. COMMW SCIENT IND RES ORG (AU) 1985-09-16 EP disclosed
EP-0146556-A1 POTENTIATION OF ANTHELMINTICS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 1985-07-03 EP disclosed
WO-1984004455-A1 POTENTIATION OF ANTHELMINTICS COMMW SCIENT IND RES ORG (AU) 1984-11-22 WO disclosed
EP-0090368-A1 Anthelmintic preparations HOECHST UK LIMITED (GB) 1983-10-05 EP disclosed
US-4331652-A COPOLYMERIC MATRIX DERIVED FROM LACTIC ACID AND GLYCOLIC ACID ELI LILLY AND COMPANY (US) 1982-05-25 US disclosed
US-4127664-A BENZIMIDAZOLES E. R. SQUIBB & SONS, INC. (US) 1978-11-28 US disclosed
US-4076827-A Method of treating helminthiasis by parenteral administration of sulfoxide derivatives of benzimidazoles E. R. SQUIBB & SONS, INC. (US) 1978-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180326072-A1 ANTI-PROTOZOAL COMPOUNDS AND USES THEREOF PPIP5K2, PIGS, PGLS NPC1 4439/4885RAB9A 2772/4885PKM 214/4885
US-20220008542-A1 ANTI-PROTOZOAL COMPOUNDS AND USES THEREOF PPIP5K2, PIGS, PGLS NPC1 4439/4885RAB9A 2772/4885PKM 214/4885
US-11160867-B2 Anti-protozoal compounds and uses thereof PPIP5K2, PIGS, PGLS NPC1 4439/4885RAB9A 2772/4885PKM 214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.